-
World No.1 Sinner pulls out of Shanghai Masters to delay return
-
Ethiopia's Tigray rebels abandon regional capital as govt advances
-
Red Bull's Verstappen grabs pole position for Bahrain GP
-
Bulgaria's Tsar Samuel returns 'home' after 1,000 years
-
India beat Pakistan in blockbuster as golfer Kim wins 'crazy' gold
-
'Glad it's over': Kim powers to Games gold and military exemption
-
India beat arch-rivals Pakistan to win Asian Games cricket gold
-
After 11 World Cups, football finally comes home for one Indian fan
-
Ethiopia's Tigray rebels abandon regional capital as govt advances: journalist
-
Marc Marquez wins sprint at Japan MotoGP, Martin grabs pole
-
Tom Kim powers to Games gold and exemption from military service
-
Alcaraz fends off Arnaldi to reach Japan Open quarters
-
Split loyalties for Indian football fans at Brazil friendly
-
Antonelli tops times in final practice at Bahrain GP
-
India-Pakistan blockbuster brings cricket fever to Japan baseball field
-
Gauff digs deep to beat Osorio in China Open second round
-
Wong waiting on Rafa after winning Asian Games tennis gold
-
Fresh protests to hit Spain after housing measures defeated
-
With Russia next door and rising costs, Latvia goes to the polls
-
'He's here with me': Japan cycle queen dedicates gold to late brother
-
Penalty hero rues empty seats as Games hosts Japan win football gold
-
Japan Olympic chief says 'lot more' athletes at Games than expected
-
North Korea fires ballistic missile after Seoul's apology demand
-
Asian carmakers besting US rivals at home, China poised to strike
-
US regulator finds Boeing 737 MAX software bug 'not a safety concern'
-
Widgets & Web Offers All-Inclusive Investor Relations Websites for Public Companies, IPOs and SPACs
-
Ohtani 'managing' injuries as Dodgers launch MLB post-season
-
Adams named new US captain to 2030 World Cup
-
Botched US execution leaves murderer unconscious on ventilator: lawyers
-
China a better influence in Latin America than US: poll
-
Cornell rape case exposes sexual violence at US colleges
-
Judge pauses construction of border project in Texas national park
-
France held by Italy in Zidane's homecoming after Olise stunner
-
Belgium's De Bruyne fires double to sink Turkey, France held by Italy
-
Ethiopian pro-government militia claims Tigray airport as regional tensions spike
-
US jobs data boosts stocks as oil prices dip
-
Ohtani shaking off injuries as Dodgers launch MLB post-season
-
US Supreme Court to hear high-stakes climate case
-
Sea levels to rise in California as coastal wave surges up west coast
-
Trump expected to name intel chief Clayton as AI czar: reports
-
New rallies urged in France as protests disrupt over 730 schools
-
Argentina unveils passports-for-investment scheme
-
Djokovic survives China Open scare, Sabalenka starts strong
-
Brazil election debate chaos sparks censorship row
-
King Charles to evoke colonial 'darkest days' on Caribbean tour
-
England's Carse charged by cricket body over nightclub incident
-
Tesla shares jump after global car sales top estimates
-
Amazon vows $1 bn for data center towns, decries 'myths'
-
DR Congo Ebola outbreak killed more than 4,000: official figures
-
Oil prices drop on G7 fuel release, US jobs data boosts stocks
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
O.Gaspar--PC